Diazepam tapering in detoxification for high-dose benzodiazepine abuse.
The clinical characteristics and management of patients who abuse high doses of benzodiazepines are not well described. In a prospective open study, 23 subjects who abused high doses of benzodiazepines were admitted for detoxification. Urine or blood test results confirmed benzodiazepine use in all but one subject and multiple drug use in eight (35%). Median benzodiazepine dose was 150 mg (range 40 to 500 mg) of diazepam equivalent. Initial plasma concentrations (diazepam: median = 1245 ng/ml; desmethyldiazepam: median = 2961 ng/ml) were 400% to 800% higher than usual therapeutic concentrations. For detoxification, subjects were given a loading dose of diazepam equal to approximately 40% their reported daily consumption. This was followed with daily tapering of diazepam by 10%. This regimen resulted in a slow and gradual decline in drug concentrations. Withdrawal symptoms were assessed daily. Sixteen subjects completed detoxification in the hospital without complications. One subject became paranoid and confused on day 7 of withdrawal. This was attributed to a too-low initial loading dose and too-rapid tapering, which resulted in rapid drug elimination. Gradual reduction of diazepam dose appears to be an effective and safe approach for detoxifying abusers of high doses of benzodiazepines.
D000328:Adult; D001569:Benzodiazepines; D003975:Diazepam / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008658:Inactivation, Metabolic; D007700:Kinetics; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D003708:Nordazepam / Q000097:blood; D011446:Prospective Studies; D019966:Substance-Related Disorders / Q000188:drug therapy*
D001569:Benzodiazepines; D003708:Nordazepam; D003975:Diazepam